MedPath

Effect of Probiotics on Mycoplasma Pneumoniae Pneumonia

Not Applicable
Not yet recruiting
Conditions
Mycoplasma Pneumoniae Pneumonia
Interventions
Dietary Supplement: Placebo
Dietary Supplement: Probiotic
Registration Number
NCT06348095
Lead Sponsor
Wecare Probiotics Co., Ltd.
Brief Summary

To evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with mycoplasma pneumoniae pneumonia, in comparison with placebo.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
72
Inclusion Criteria
  1. Meet the diagnostic criteria for pneumonia in "Zhufutang Practical Pediatrics" (7th Edition), and is diagnosed with Mycoplasma pneumoniae pneumonia using tNGS technology;
  2. Infants and young children aged 6 months to 3 years;
  3. The course of the disease is <48 h;
  4. The family members of the children are informed about the study and sign the informed consent form.
Read More
Exclusion Criteria
  1. Previous history of wheezing;
  2. Cardiovascular disease and congenital tracheal dysplasia;
  3. pneumonia induced by other causes;
  4. Dysplasia of bronchial and pulmonary tracts;
  5. premature infants;
  6. Combined with immunosuppressive diseases;
  7. Presence of mental illness.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo groupPlaceboMaltodextrin, one strip/ day WecProB, before meals; Storage: Store in a cool, dry place without sun exposure.
Probiotics groupProbiotic2B CFU/ strip/ day WecProB, before meals; Storage: Store in a cool, dry place without sun exposure.
Primary Outcome Measures
NameTimeMethod
Mycoplasma pneumoniae load7天

Mycoplasma pneumoniae load was detected by tNGS

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath